The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC).
 
Konstantin Dragnev
Research Funding - Amgen (Inst); Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Molecular Templates (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Mustafa Erman
Consulting or Advisory Role - Abdi Ibrahim (Inst); Astellas Amgen BioPharama (Inst); Bristol-Myers Squibb (Inst); DevaCell (Inst); Eczacibasi (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Speakers' Bureau - Abdi Ibrahim (Inst); Astellas Amgen BioPharama (Inst); Bristol-Myers Squibb (Inst); DevaCell (Inst); Eczacibasi (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Abdi Ibrahim; Astellas Amgen BioPharama; Bristol-Myers Squibb; DevaCell; Eczacibasi; Janssen; Merck; MSD; Nobelpharma; Novartis; Pfizer; Roche
 
Emilio Bria
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celltrion; Lilly; MSD Oncology; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Jay Lee
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Foundation Medicine; Genentech/Roche; Lilly; Merck; Novartis; Regeneron
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; Genentech/Roche
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Novartis; Tempus AI, Inc.
Patents, Royalties, Other Intellectual Property - UCLA Patents
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Novartis
 
Cole Manschot
Employment - Employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
 
Jeffrey Thompson
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Ayman Samkari
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Jonathan Spicer
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck